Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2373-2388

  Kanmogne, Georgette D ^a   Singh, Sangya ^a   Roy, Upal ^a   Liu, Xinming ^a   McMillan, JoEllyn ^a   Gorantla, Santhi ^a   Balkundi, Shantanu ^a   Smith, Nathan ^a   Alnouti, Yazen ^a   Gautam, Nagsen ^a   Zhou, You ^b   Poluektova, Larisa ^a   Kabanov, Alexander ^a   Bronich, Tatiana ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Antiretroviral therapy; Blood brain barrier; Folate; Monocyte endothelial cell interactions; NanoART; Nanomedicine

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CD11B ANTIGEN; EFAVIRENZ; INDINAVIR; NANOPARTICLE; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL ACTIVATION; CELL ASSAY; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GLIA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR INTERACTION; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; QUANTITATIVE ANALYSIS; VIRUS IDENTIFICATION; VIRUS LOAD;

ADULT; ANIMALS; ANTI-RETROVIRAL AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FOLIC ACID; HIV INFECTIONS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SPLEEN; TISSUE DISTRIBUTION; VIRAL LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84866486028     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29454     Document Type: Article

References (46)

1. Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol. 2009;4(4):430-447.
2. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747-1751.
3. Grant I, Sacktor N, McArthur J. HIV neurocognitive disorders. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, editors. The Neurology of AIDS. 2 ed. New York: Oxford University Press;2005:357-373.
4. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789-1799.
5. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096.
6. Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol. 2003;74(5):691-701.
7. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol. 2006;19(4):358-361.
8. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008;6(5):388-400.
9. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol. 2010;67(6):699-714.
10. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359-1366.
11. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis. 2008;197 Suppl 3:S294-S306.
12. Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release. 2009;138(1):2-15.
13. McMillan J, Batrakova E, Gendelman HE. Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci. 2011;104:563-601.
14. Bressani RF, Nowacek AS, Singh S, et al. Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology. 2011;5(4):592-605.
15. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophagebased nanoparticle platform for antiretroviral drug delivery. Blood. 2006;108(8):2827-2835.
16. Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. 2007;358(1):148-158.
17. Nowacek AS, Miller RL, McMillan J, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond). 2009;4(8): 903-917.
18. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4(5):557-574.
19. Gorantla S, Dou H, Boska M, et al. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol. 2006;80(5):1165-1174.
20. Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009;183(1):661-669.
21. Beduneau A, Ma Z, Grotepas CB, et al. Facilitated monocytemacrophage uptake and tissue distribution of superparmagnetic ironoxide nanoparticles. PLoS One. 2009;4(2):e4343.
22. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011;150(2):204-211.
23. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988;167(4):1428-1441.
24. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab. 2007;27(1): 123-134.
25. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood. 2008;111(4):2062-2072.
26. Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling. Microvasc Res. 2009;77(2):212-219.
27. Stoddart CA, Bales CA, Bare JC, et al. Validation of the SCID-hu Thy/ Liv mouse model with four classes of licensed antiretrovirals. PLoS One. 2007;2(7):e655.
28. Huang J, Gautam N, Bathena SP, et al. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(23):2332-2338.
29. Zhao R, Seither R, Brigle KE, Sharina IG, Wang PJ, Goldman ID. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J Biol Chem. 1997;272(34):21207-21212.
30. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007;28(33):4947-4967.
31. Wu D, Pardridge WM. Blood-brain barrier transport of reduced folic acid. Pharmaceutical Research. 1999;16(3):415-419.
32. Patrick TA, Kranz DM, van Dyke TA, Roy EJ. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J Neurooncol. 1997;32(2):111-123.
33. Wang X, Li J, Wang Y, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano. 2009;3(10):3165-3174.
34. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol. 2010;624:249-265.
35. Nukolova NV, Oberoi HS, Cohen SM, Kabanov AV, Bronich TK. Folatedecorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011;32(23):5417-5426.
36. Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine. 2012;8(2):212-220.
37. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release. 2000;64(1-3):27-37.
38. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother. 2002;51(3):153-162.
39. Beduneau A, Hindre F, Clavreul A, Leroux JC, Saulnier P, Benoit JP. Brain targeting using novel lipid nanovectors. J Control Release. 2008;126(1):44-49.
40. Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008;58(1):61-74.
41. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008; 25(10):2262-2271.
42. Mahajan SD, Roy I, Xu G, et al. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res. 2010;8(5):396-404.
43. Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS, Lee SC. CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol. 2006;16(4):256-265.
44. Buckner CM, Luers AJ, Calderon TM, Eugenin EA, Berman JW. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J Neuroimmune Pharmacol. 2006;1(2):160-181.
45. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011;150(2):204-211.
46. Balkundi S, Nowacek AS, Veerhubotla RS, et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine. 2011;6:3393-3404.